A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes. Reading time 2 minutes The case for Ozempic as a dementia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results